BioSpace News Archive

First presentation of findings from EPI03, EPI04 and EPI07 studies that examine the pharmacokinetics and pharmacodynamics of single and repeat administration of epinephrine after intranasal, intramuscular and subcutaneous administration

Advocare, a physician-owned multi-specialty group with nearly 600 providers, continues to expand its footprint in New Jersey and Pennsylvania by welcoming five new independent physician practices into the organization.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA” (TSX VENTURE: IPA) (OTC QB: IPATF), through its subsidiary, Talem Therapeutics (talemtherapeutics.com), and the New York-based company EVQLV, Inc. (evqlv.com), announces a new collaboration aimed at accelerating the global effort to develop lead therapeutic and vaccine candidates against the SARS-CoV-2 virus.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its fourth quarter and full year 2019 financial results on Monday, March 9, 2020.

DENTSPLY SIRONA Inc., The Dental Solutions Company, announced its financial results for the three and twelve months ended December 31, 2019.

Zhongchao Inc. announced that Network 1 Financial Securities, Inc., who acted as the lead underwriter and bookrunner of the Company’s initial public offering, has partially exercised their over-allotment option and purchased an additional 315,003 Class A ordinary shares at the IPO price of $4.00 per share.

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the St. Marianna University School of Medicine Toyoko Hospital, a hospital in the greater Tokyo metropolitan area, has entered into an agreement to lease and utilize a Senhance® Surgical System.

Theravance Biopharma, Inc. (NASDAQ: TBPH)today announced the closing of a private placement of $400 million of non-recourse Triple II 9.5% fixed rate term notes.

Series B Proceeds will Advance XTX201 (Tumor-Selective IL-2) and XTX101 (Tumor-Selective aCTLA4) into the Clinic while Expanding Xilio’s Tumor-Selective Cytokine Pipeline

International medical imaging IT and cybersecurity company Sectra has signed a digital pathology contract with Geneva University Hospital in Switzerland.